BackStrongbridge Biopharma plc Overview

Strongbridge Biopharma plc Other Current Assets

Strongbridge Biopharma plc's other current assets is $1.7M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$1.67M
12.96% YoYΔ $-248000.00 vs prior year quarter

Peer average / median

Loading

Strongbridge Biopharma plc Other Current Assets History

Loading

Strongbridge Biopharma plc vs. peers: Other Current Assets Comparison

Loading

Strongbridge Biopharma plc Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Strongbridge Biopharma plc (SBBP) FAQ

Strongbridge Biopharma plc posts a other current assets of $1.7M as of June 2021. That compares with $1.9M in the prior-year period — down 13.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Strongbridge Biopharma plc's other current assets was $1.9M. The latest reading is $1.7M — a 13.0% year-over-year decrease (period ending June 2021). Use the history and growth charts on this page for a longer lookback.

Other Current Assets is one piece of Strongbridge Biopharma plc's financial statement story. At $1.7M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SBBP's other current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Strongbridge Biopharma plc's other metric pages and overview cover the third.

Judging Strongbridge Biopharma plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current assets easier to interpret. Start with $1.7M here, then scan peer and history charts to see if the gap is persistent.